Caribou Biosciences Provides Regulatory Update on B Cell Lymphoma Phase 3

 Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a comparator arm of immunochemotherapy followed by HDCT and ASCT --

-- ANTLER Phase 1 trial continues dose expansion enrollment; initial dose expansion data and RP2D expected Q2 2024 --

-- Caribou plans to initiate Phase 3 pivotal trial by YE 2024 --

https://www.marketscreener.com/quote/stock/CARIBOU-BIOSCIENCES-INC-125041251/news/Caribou-Biosciences-Provides-Regulatory-Update-on-CB-010-Pivotal-Plan-with-Phase-3-Trial-Initiation-45553818/